JT 07 - JYANT TechnologiesAlternative Names: JT07
Latest Information Update: 12 Aug 2016
At a glance
- Originator JYANT Technologies
- Class Antibodies
- Mechanism of Action CXCR3 receptor antagonists; CXCR7 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Solid tumours
Most Recent Events
- 12 Aug 2016 Preclinical trials in Solid tumours in USA (unspecified route)
- 12 Aug 2016 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)